2012
DOI: 10.3892/or.2012.1686
|View full text |Cite
|
Sign up to set email alerts
|

Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration

Abstract: Abstract. The aim of this study was to investigate the effect of fasudil on lung carcinoma-conditioned endothelial cells (LCc-ECs). To obtain LCc-ECs, human umbilical vein endothelial cells (HUVECs) were treated with conditioned cell culture media from human A549 lung adenocarcinoma cells. The effect of fasudil on the viability of LCc-ECs was assessed using the MTT assay, in vitro invasive ability was evaluated using the transwell chamber assay and cytoskeletal changes were detected using fluorescein-labelled … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 21 publications
1
6
0
Order By: Relevance
“…On the other hand, the same treatment with ARA-S increased (50%) Akt kinase activity. Our studies are consistent with the findings that cannabinoid ligands (stable analogues of anandamide or CB-1 ligands) reduced Rho/ROCK kinase, stimulated PI3/Akt kinase, reorganized cytoskeleton (actin) and decreased cell migration [15] , [16] , [17] . These findings are also in agreement with reports that Rho kinase inhibition leads to rapid activation of PI3/Akt pathway [18] .…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…On the other hand, the same treatment with ARA-S increased (50%) Akt kinase activity. Our studies are consistent with the findings that cannabinoid ligands (stable analogues of anandamide or CB-1 ligands) reduced Rho/ROCK kinase, stimulated PI3/Akt kinase, reorganized cytoskeleton (actin) and decreased cell migration [15] , [16] , [17] . These findings are also in agreement with reports that Rho kinase inhibition leads to rapid activation of PI3/Akt pathway [18] .…”
Section: Discussionsupporting
confidence: 92%
“…4 ). Many studies have also demonstrated that Rho/ROCK activation or reduction of its activity plays a major role in these processes [17] , [23] . Indeed, our results (as shown in Fig.…”
Section: Discussionmentioning
confidence: 99%
“…ROCK inhibitors fasudil and Y27632 have been extensively used in studies using cancer cell lines and rodent cancer models, and significant beneficial effects have been shown in many types of cancers (Chen et al 2014 ; Kale et al 2015 ; Mali et al 2014 ; Matsuoka and Yashiro 2014 ; Morgan-Fisher et al 2013 ; Rath and Olson 2012 ; Schofield and Bernard 2013 ) (Table 4 ). Recent experimental studies have further supported fasudil as a drug candidate for hematological malignancies (Mali et al 2011 ; Oku et al 2014 ; Wermke et al 2015 ), lung cancers (Yang et al 2010 , 2012 ; Zhang et al 2012 ; Zhu et al 2011 ), bladder cancer (Abe et al 2014 ), glioma (Nakabayashi and Shimizu 2011 ), hepatocellular carcinoma (Takeba et al 2012 ), and ovarian cancer (Ogata et al 2009 ). Several novel ROCK inhibitors were tested as an anti-cancer therapy (Table 4 ).…”
Section: Promising Potential Of Rock Inhibition In Cancer Therapymentioning
confidence: 99%
“…Y-27632 treatment in melanoma significantly changed 94 gene transcripts, many of which are involved in tumor initiation and progression, indicating that ROCK signaling also contributes to the tumor transcriptome in addition to its well-established role in the regulation of F-actin dynamics (Spencer et al 2011 ). In lung cancer, fasudil treatment inhibited the growth of 95D lung carcinoma cells (Yang et al 2010 ); it also significantly attenuated angiogenesis as it inhibited lung carcinoma-conditioned endothelial cell proliferation and in vivo invasive ability by causing stress fiber fracture and breakage (Zhang et al 2012 ). Moreover, ROCK inhibition may also decrease tumor cell proliferation by preventing the activation of oncogenes.…”
Section: Rock Is a Key Player In Cancer Progressionmentioning
confidence: 99%
“…Fasudil, Wf-536, Y-27632, and, most recently, RKI-1447 have all been shown to reduce tumor progression of hepatocellular and lung carcinomas, myeloma, and breast cancers in mice (Itoh et al 1999; Takamura et al 2001; Nakajima et al 2003; Ying et al 2006; Patel et al 2012). Fasudil and Wf-536 also attenuate cancer-associated angiogenesis in vivo and in vitro lung carcinoma models (Nakajima et al 2003; Zhang Z et al 2012). Administration of Slx-2119, a potent selective ROCK II inhibitor, in a human tumor xenograft model resulted in a significant dose-dependent delay in tumor growth with acceptable toxicity (Shifrin et al 2005; Boerma et al 2008).…”
Section: Rocks: Potential Targets For Cancer Treatment?mentioning
confidence: 99%